VALN - FDA finds no issues in Pfizer/ Valneva Lyme disease vaccine trial
2023-10-11 14:10:27 ET
More on Pfizer, Valneva, etc.
- Valneva's Vaccination Valor: A Buy Rating Justified
- Pfizer: Sell-Off Overdone, Healthy Pipeline To Sustain Above 15% ROE
- Pfizer Inc. (PFE) CEO Albert Bourla Presents at Cantor Fitzgerald Annual Global Health Conference (Transcript)
- Dividend Roundup: McDonald’s, Pfizer, Delta Air Lines, Oracle, and more
- Pfizer expected to certify compliance with FTC on Seagen deal in 2-3 weeks - report
For further details see:
FDA finds no issues in Pfizer/ Valneva Lyme disease vaccine trial